A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aramchol in Subjects With Hepatic Impairment
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Icomidocholic acid (Primary)
- Indications Cholelithiasis; Fibrosis; Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Galmed Research and Development, Ltd.
- 14 Aug 2024 Status changed from recruiting to completed.
- 08 Feb 2021 Planned End Date changed from 1 Jan 2021 to 1 Jul 2021.
- 08 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.